An FDA document related to CBD that had been pending for several months before the White House has been withdrawn, consistent with a freeze on regulations and guidance documents issued by the administration of President Joe Biden.
While stakeholders had not seen the actual document “Cannabidiol Enforcement Policy; Draft Guidance for Industry” pending before the White House’s Office of Management and Budget (OMB) since July, many were hopeful that publication of the guidance would help provide some measure of certainty to an industry operating for years in a state of regulatory limbo at the national level.
Withdrawal of the policy highlights “two years have passed since the 2018 Farm Bill made CBD legal, and FDA has made no meaningful progress on a clear regulatory path for CBD consumer products,” said Duffy MacKay, senior vice president of scientific and regulatory affairs with San Diego-based CV Sciences Inc., a marketer of hemp-based CBD products, in an email. “In my